Topic is suspended
Status Suspended
Process TAG
ID number 3756


Key events during the development of the guidance:

Date Update
29 May 2020 The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of Nivolumab with ipilimumab for neoadjuvant treatment of early non-small-cell lung cancer. For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the European Medicines Agency for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes.
29 May 2020 Suspended. Topic is suspended
10 March 2020 In progress. Topic is in progress

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance